Primary hyperaldosteronism epidemiology and demographics: Difference between revisions
Usama Talib (talk | contribs) No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
== Overview == | == Overview == | ||
Worldwide, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) ranges from a low of 10,000 per 100,000 persons with hypertension to a high of 35,000 per 100,000 persons with hypertenion when aldosterone/renin ratio is used as a screening tool.<sup>[[Primary hyperaldosteronism epidemiology and demographics#cite note-pmid17161262-1|[1]]]</sup> | |||
== Epidemiology and Demographics == | == Epidemiology and Demographics == | ||
Revision as of 21:52, 19 July 2017
|
Primary hyperaldosteronism Microchapters |
|
Differentiating Primary Hyperaldosteronism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary hyperaldosteronism epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Primary hyperaldosteronism epidemiology and demographics |
|
FDA on Primary hyperaldosteronism epidemiology and demographics |
|
CDC on Primary hyperaldosteronism epidemiology and demographics |
|
Primary hyperaldosteronism epidemiology and demographics in the news |
|
Blogs on Primary hyperaldosteronism epidemiology and demographics |
|
Risk calculators and risk factors for Primary hyperaldosteronism epidemiology and demographics |
Overview
Worldwide, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) ranges from a low of 10,000 per 100,000 persons with hypertension to a high of 35,000 per 100,000 persons with hypertenion when aldosterone/renin ratio is used as a screening tool.[1]
Epidemiology and Demographics
Prevalence
- Worldwide, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) ranges from a low of 10,000 per 100,000 persons with hypertension to a high of 35,000 per 100,000 persons with hypertenion when aldosterone/renin ratio is used as a screening tool.[1]
- In patients with resistant hypertension, the prevalence of Conn's syndrome (Primary hyperaldosteronism-PA) is reported to be even higher, ranging from a low of 17,000 per 100,000 patients to a high of 23,000 per 100,000 patients.[2]
- FH1 accounts for 0.5 to 1.0% of PA and occurs equally among women and men [3]
- The prevalence of FH2 ranges from 1.2 to 6% in adult populations of PA [4]
Incidence
Case-Fatality rate
Age
Gender
Race
- There is no racial predilection for Conn's syndrome (Primary hyperaldosteronism-PA).[5]
- Blacks have been found to have lower plasma renin activity than other populations.[6]
Geographic Distribution
References
- ↑ Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F (2006). "A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients". J. Am. Coll. Cardiol. 48 (11): 2293–300. doi:10.1016/j.jacc.2006.07.059. PMID 17161262.
- ↑ Stowasser M, Taylor PJ, Pimenta E, Ahmed AH, Gordon RD (2010). "Laboratory investigation of primary aldosteronism". Clin Biochem Rev. 31 (2): 39–56. PMC 2874431. PMID 20498828.
- ↑ "Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic".
- ↑ Stowasser M, Gordon RD (2000). "Primary aldosteronism: learning from the study of familial varieties". J. Hypertens. 18 (9): 1165–76. PMID 10994747.
- ↑ Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P (2002). "Hyperaldosteronism among black and white subjects with resistant hypertension". Hypertension. 40 (6): 892–6. PMID 12468575.
- ↑ Lee MR, Critchley JA, Gordon CJ, Makarananda K, Sriwatanakul K, Balali-Mood M, Boye GL (1990). "Ethnic differences in the renal sodium dopamine relationship. A possible explanation for regional variations in the prevalence of hypertension?". Am. J. Hypertens. 3 (6 Pt 2): 100S–103S. PMID 2383374.